Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Revenue		$ 850,000
Costs and expenses:
Research and development	$ 2,966,000	5,513,000
General and administrative	1,628,000	1,577,000
Total costs and expenses	4,594,000	7,090,000
Loss from operations	(4,594,000)	(6,240,000)
Interest expense	(1,000)	(332,000)
Other income (expense), net		(2,000)
Loss before provision for income taxes	(4,595,000)	(6,574,000)
Provision for income taxes	0	0
Net loss	(4,595,000)	(6,574,000)
Net loss attributable to noncontrolling interests	0	0
Net loss attributable to Vaccinex, Inc. common stockholders	(4,595,000)	(6,574,000)
Comprehensive loss	$ (4,595,000)	$ (6,574,000)
Net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted	$ (0.12)	$ (0.26)
Weighted-average shares used in computing net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted	38,758,283	25,216,788